In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on ADMA Biologics (NASDAQ: ADMA), with a price target of $12. The company’s shares opened today at $6.50, close to its 52-week high of $6.86.
McCarthy noted:
“ADMA announced that the company’s compliance status for its immunoglobulin manufacturing facility in Florida has improved to “Voluntary Action Indicated”. We view this as a significant positive.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 18.7% and a 52.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
ADMA Biologics has an analyst consensus of Strong Buy, with a price target consensus of $10.63, representing a 63.5% upside. In a report released today, Oppenheimer also reiterated a Buy rating on the stock with a $13 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.86 and a one-year low of $2.01. Currently, ADMA Biologics has an average volume of 326.6K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADMA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.
